Zhen Yang

Dr. Zhen Yang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
CWChangshan Wan
Changshan Wan
QWQiuyan Wu
Qiuyan Wu
YWYali Wang
Yali Wang
YSYan Sun
Yan Sun
TJTao Ji
Tao Ji
WZWeilong Zhong
Weilong Zhong

25 October 2024 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
RLRuxue Liu
Ruxue Liu
MQMinghan Qiu
Minghan Qiu
XDXinxin Deng
Xinxin Deng
MZMeng Zhang
Meng Zhang
ZGZhanhua Gao
Zhanhua Gao
HWHuaqing Wang
Huaqing Wang
Pancreatic cancer is a malignant tumor of the digestive tract with a high mortality rate. Erianin has antitumor activity, but the regulatory targets and mechanism of action in pancreatic cancer are unclear. The objective of this study was to evaluate the anti-pancreatic cancer activity of Erianin and explore its underlying mechanisms. A network pharmacology approach was used to investigate the mechanism of action of Erianin in pancreatic cancer cells. Cell proliferation was analyzed using CCK8, colony-formation, and EdU proliferation assays. Cell migration was evaluated through wound healing and transwell assays, as well as determination of the protein expression levels of EMT markers and β-catenin. Apoptosis and the cell cycle were measured using flow cytometry and JC-1 staining, respectively. The protein expression levels of p-Rb, CyclinB1, P21, Cleaved-PARP, and Cleaved-Caspase3 were assessed using western blotting. RNA sequencing (RNA-seq) and bioinformatics analyses were performed to elucidate the mechanism underlying the action of Erianin in pancreatic cancer. Western blotting was used to examine the expression levels of key proteins in the AKT, JNK, and p38 MAPK signaling pathways. Molecular docking and CETSA were used to test hypotheses. The tumor-suppressive ability of Erianin in vivo was assessed using a tumor-bearing assay in nude mice. Network pharmacology revealed that Erianin inhibited pancreatic cancer through multiple pathways. Erianin significantly inhibited pancreatic cancer cell proliferation and migration while promoting intracellular ROS and inducing apoptosis. Mechanistically, Erianin inhibited pancreatic cancer cell proliferation by regulating the AKT/FOXO1 and ASK1/JNK/p38 MAPK signaling pathways. In vivo experiments showed that Erianin inhibited subcutaneous tumor growth and promoted tumor tissue apoptosis in nude mice. The component-target-pathway network revealed that Erianin exerted anti-cancer effects through multiple components, targets, and pathways. Erianin inhibited the proliferation and migration of pancreatic cancer cells and induced apoptosis through the AKT/FOXO1 and ASK1/JNK/p38 MAPK signaling pathways. These results indicate that Erianin is a promising agent for pancreatic cancer treatment.

6 January 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ZYZhen Yang
Zhen Yang
HLHonglin Li
Honglin Li
JHJie Hao
Jie Hao
HMHanwei Mei
Hanwei Mei
MQMinghan Qiu
Minghan Qiu
MGMing Gao
Ming Gao
Pancreatic cancer (PC) has become a worldwide challenge attributed to its difficult early diagnosis and rapid progression. Treatments continue to be limited besides surgical resection. Hence, we aimed to discover novel biological signatures as clinically effective therapeutic targets for PC via the mining of public tumor databases. We found that epiphycan (EPYC) could function as an independent risk factor to predict the poor prognosis in PC based on integrated bioinformatics analysis. We downloaded associated PC data profiles from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) online websites, then applied the software Rstudio to filter out genes under the strict criteria. After the batch survival analysis using Log-rank test and univariate cox regression, we obtained 39 candidate genes. Subsequently, we narrowed the scope to 8 genes by establishing a Lasso regression model. Eventually, we focused on 2 genes (EPYC and MET) by further building a multivariate cox regression model. Given that the role of EPYC in PC remains obscure, we then performed a series of molecular functional experiments, including RT-qPCR, CCK8, EdU, colony formation, Transwell, western blot, cell live-dead staining, subcutaneous tumor formation, to enhance our insight into its underlying molecular mechanisms. The above results demonstrated that EPYC was highly expressed in PC cell lines and could promote the proliferation of PCs via PI3K-AKT signaling pathway in vivo and in vitro. We arrived at a conclusion that EPYC was expected to be a biological neo-biomarker for PC followed by being a potential therapeutic target.

19 February 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
CLChenying Lin
Chenying Lin
HAHaohua An
Haohua An
JLJingna Lin
Jingna Lin
YCYuejuan Cao
Yuejuan Cao
ZYZhen Yang
Zhen Yang
Introduction: This study evaluated the incidence trends of early-onset (diagnosed at ages 15-39) and late-onset (diagnosed at age 40 and above) type 2 diabetes mellitus (T2DM) in the Asia-Pacific region, including the World Health Organization (WHO) South-East Asia Region (SEARO) and Western Pacific Region (WPRO), and assessed the impact of the COVID-19 pandemic.Methods: Using data from the Global Burden of Diseases Study (GBD) 2021, we analyzed trends in age-standardized incidence rate (ASIR) using Join point regression to determine annual percentage change (APC). To assess the pandemic’s impact, we calculated excess incidence for 2020 and 2021 by subtracting predicted ASIR from observed ASIR.Results: In recent years, particularly during the COVID-19 pandemic, the ASIR for early-onset T2DM in the Asia-Pacific region accelerated significantly. SEARO’s APC rose from 2.24% between 2011-2019 to 5.45% between 2019-2021. Similarly, WPRO’s APC increased from 1.71% between 1999-2017 to 5.01% between 2017-2021. In 2021, the ASIR for early-onset T2DM was 269.6 per 100,000 in WPRO and 248.4 per 100,000 in SEARO. Conversely, late-onset T2DM ASIR growth in SEARO slowed after 2017 (APC 1.92% for 2005-2017 vs. 1.04% for 2017-2021), while WPRO saw a decline (APC 1.06% for 2007-2017 vs. -1.10% for 2017-2021). During the COVID-19 pandemic in 2020 and 2021, the observed ASIR of early-onset T2DM in the Asia-Pacific region exceeded historical predictions, showing a positive excess in ASIR.Conclusions: This study reveals a significant recent increase in early-onset T2DM incidence in the Asia-Pacific region, highlighting the need for targeted public health interventions.

15 September 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
QSQi Sun
Qi Sun
ZYZhen Yang
Zhen Yang
MQMinghan Qiu
Minghan Qiu
SWShoujun Wang
Shoujun Wang
XZXingli Zhao
Xingli Zhao
MGMing Gao
Ming Gao

4 September 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
QZQiaonan Zhang
Qiaonan Zhang
MQMinghan Qiu
Minghan Qiu
JLJinpu Liu
Jinpu Liu
ZGZhanhua Gao
Zhanhua Gao
YLYuya Liu
Yuya Liu
MGMing Gao
Ming Gao
Introduction: Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid malignancy characterized by rapid progression, resistance to conventional therapies, and poor patient prognosis. There is an urgent need for innovative therapeutic strategies. Erianin, a natural compound derived from Dendrobium, has demonstrated significant anti-tumor effects in various cancers, yet its role in ATC remains unexplored.Methods: The anti-tumor effects of erianin were assessed in vitro through assays including CCK-8, colony formation, flow cytometry, LDH release, and Western blot. RNA sequencing was conducted for gene expression analysis. Immunofluorescence and transmission electron microscopy evaluated pyroptosis markers. In vivo efficacy was validated in CAL62 xenograft mouse models using tumor growth measurement, TUNEL staining, and immunohistochemistry.Results: Erianin significantly inhibited proliferation and colony formation, induced G2/M cell cycle arrest, apoptosis, and GSDME-dependent pyroptosis in ATC cells. Mechanistically, erianin suppressed activation of the MAPK/ERK and PI3K/AKT signaling pathways. Importantly, erianin synergistically enhanced the anti-tumor efficacy of anlotinib in ATC cells. In vivo, combination therapy with erianin and anlotinib resulted in marked tumor growth suppression and increased apoptosis compared to monotherapies.Conclusion: Collectively, our study demonstrates that erianin exerts potent anti-tumor activity in ATC by simultaneously inhibiting the MAPK/ERK and PI3K/Akt signaling pathways, thereby inducing apoptosis and GSDME-dependent pyroptosis. Furthermore, the synergistic interaction between erianin and anlotinib significantly enhances therapeutic efficacy. These findings position erianin as a promising candidate for the treatment of ATC, offering novel therapeutic insights and supporting further clinical investigations.